233 related articles for article (PubMed ID: 26386707)
1. Health-related quality of life in patients with metastatic, relapsed, or inoperable squamous cell carcinoma of the head and neck in India.
Noronha V; Joshi A; Marfatia S; Patil V; Juvekar S; Arya S; Banavali S; Prabhash K
Support Care Cancer; 2016 Apr; 24(4):1595-602. PubMed ID: 26386707
[TBL] [Abstract][Full Text] [Related]
2. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.
Harrington KJ; Ferris RL; Blumenschein G; Colevas AD; Fayette J; Licitra L; Kasper S; Even C; Vokes EE; Worden F; Saba NF; Kiyota N; Haddad R; Tahara M; Grünwald V; Shaw JW; Monga M; Lynch M; Taylor F; DeRosa M; Morrissey L; Cocks K; Gillison ML; Guigay J
Lancet Oncol; 2017 Aug; 18(8):1104-1115. PubMed ID: 28651929
[TBL] [Abstract][Full Text] [Related]
3. Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048.
Rischin D; Harrington KJ; Greil R; Soulières D; Tahara M; de Castro G; Psyrri A; Braña I; Neupane P; Bratland Å; Fuereder T; Hughes BGM; Mesía R; Ngamphaiboon N; Rordorf T; Ishak WZW; Hong RL; Mendoza RG; Jia L; Chirovsky D; Norquist J; Jin F; Burtness B
Oral Oncol; 2022 May; 128():105815. PubMed ID: 35381576
[TBL] [Abstract][Full Text] [Related]
4. Short-term health-related quality of life and symptom control with docetaxel, cisplatin, 5-fluorouracil and cisplatin (TPF), 5-fluorouracil (PF) for induction in unresectable locoregionally advanced head and neck cancer patients (EORTC 24971/TAX 323).
van Herpen CM; Mauer ME; Mesia R; Degardin M; Jelic S; Coens C; Betka J; Bernier J; Remenar E; Stewart JS; Preiss JH; van den Weyngaert D; Bottomley A; Vermorken JB;
Br J Cancer; 2010 Oct; 103(8):1173-81. PubMed ID: 20842129
[TBL] [Abstract][Full Text] [Related]
5. Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Mesía R; Rivera F; Kawecki A; Rottey S; Hitt R; Kienzer H; Cupissol D; De Raucourt D; Benasso M; Koralewski P; Delord JP; Bokemeyer C; Curran D; Gross A; Vermorken JB
Ann Oncol; 2010 Oct; 21(10):1967-1973. PubMed ID: 20335368
[TBL] [Abstract][Full Text] [Related]
6. A 12 country field study of the EORTC QLQ-C30 (version 3.0) and the head and neck cancer specific module (EORTC QLQ-H&N35) in head and neck patients. EORTC Quality of Life Group.
Bjordal K; de Graeff A; Fayers PM; Hammerlid E; van Pottelsberghe C; Curran D; Ahlner-Elmqvist M; Maher EJ; Meyza JW; Brédart A; Söderholm AL; Arraras JJ; Feine JS; Abendstein H; Morton RP; Pignon T; Huguenin P; Bottomly A; Kaasa S
Eur J Cancer; 2000 Sep; 36(14):1796-807. PubMed ID: 10974628
[TBL] [Abstract][Full Text] [Related]
7. A prospective randomized phase II study comparing metronomic chemotherapy with chemotherapy (single agent cisplatin), in patients with metastatic, relapsed or inoperable squamous cell carcinoma of head and neck.
Patil VM; Noronha V; Joshi A; Muddu VK; Dhumal S; Bhosale B; Arya S; Juvekar S; Banavali S; D'Cruz A; Bhattacharjee A; Prabhash K
Oral Oncol; 2015 Mar; 51(3):279-86. PubMed ID: 25578869
[TBL] [Abstract][Full Text] [Related]
8. Metronomic palliative chemotherapy in locally advanced, recurrent and metastatic head-and-neck cancer: A single-arm, retrospective study of a regional cancer center of North India (Asia).
Harsh KK; Maharia SR; Nirban RK; Khatri P; Beniwal S; Kumar HS; Jakhar SL
J Cancer Res Ther; 2020; 16(3):559-564. PubMed ID: 32719267
[TBL] [Abstract][Full Text] [Related]
9. Patients' experience of recurrent/metastatic head and neck squamous cell carcinoma and their perspective on the EORTC QLQ-C30 and QLQ-H&N35 questionnaires: a qualitative study.
Degboe A; Knight SL; Halling K; Trigg A; Al-Zubeidi T; Aldhouse N; Kitchen H; Wirth L; Rogers SN
J Patient Rep Outcomes; 2017; 2():33. PubMed ID: 30148250
[TBL] [Abstract][Full Text] [Related]
10. An international phase 3 trial in head and neck cancer: quality of life and symptom results: EORTC 24954 on behalf of the EORTC Head and Neck and the EORTC Radiation Oncology Group.
Bottomley A; Tridello G; Coens C; Rolland F; Tesselaar ME; Leemans CR; Hupperets P; Licitra L; Vermorken JB; Van Den Weyngaert D; Truc G; Barillot I; Lefebvre JL
Cancer; 2014 Feb; 120(3):390-8. PubMed ID: 24452673
[TBL] [Abstract][Full Text] [Related]
11. Quality of life scores as prognostic factors of overall survival in advanced head and neck cancer: analysis of a phase III randomized trial of pemetrexed plus cisplatin versus cisplatin monotherapy.
Urba S; Gatz J; Shen W; Hossain A; Winfree K; Koustenis A; Peterson P; Cohen EE
Oral Oncol; 2012 Aug; 48(8):723-9. PubMed ID: 22414289
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of weekly docetaxel and cisplatin in patients with advanced recurrent and metastatic head and neck cancer.
Guntinas-Lichius O; Appenrodt S; Veelken F; Krug B
Laryngoscope; 2006 Apr; 116(4):613-8. PubMed ID: 16585868
[TBL] [Abstract][Full Text] [Related]
13. Assessing quality of life in patients with head and neck cancer: cross-validation of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Head and Neck module (QLQ-H&N35).
Sherman AC; Simonton S; Adams DC; Vural E; Owens B; Hanna E
Arch Otolaryngol Head Neck Surg; 2000 Apr; 126(4):459-67. PubMed ID: 10772298
[TBL] [Abstract][Full Text] [Related]
14. Quality-of-life assessment after supradose selective intra-arterial cisplatin and concomitant radiation (RADPLAT) for inoperable stage IV head and neck squamous cell carcinoma.
Ackerstaff AH; Tan IB; Rasch CR; Balm AJ; Keus RB; Schornagel JH; Hilgers FJ
Arch Otolaryngol Head Neck Surg; 2002 Oct; 128(10):1185-90. PubMed ID: 12365891
[TBL] [Abstract][Full Text] [Related]
15. Identifying cutoff scores for the EORTC QLQ-C30 and the head and neck cancer-specific module EORTC QLQ-H&N35 representing unmet supportive care needs in patients with head and neck cancer.
Jansen F; Snyder CF; Leemans CR; Verdonck-de Leeuw IM
Head Neck; 2016 Apr; 38 Suppl 1():E1493-500. PubMed ID: 27111696
[TBL] [Abstract][Full Text] [Related]
16. Validation of the Mexican Spanish version of the EORTC QLQ-H&N35 instrument to measure health-related quality of life in patients with head and neck cancers.
Carrillo JF; Ortiz-Toledo MA; Salido-Noriega Z; Romero-Ventura NB; Ochoa-Carrillo FJ; Oñate-Ocaña LF
Ann Surg Oncol; 2013 May; 20(5):1417-26. PubMed ID: 23108555
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of health-related quality of life with EORTC QLQ-C30 and QLQ-H&N35 in Romanian laryngeal cancer patients.
Dinescu FV; Ţiple C; Chirilă M; Mureşan R; Drugan T; Cosgarea M
Eur Arch Otorhinolaryngol; 2016 Sep; 273(9):2735-40. PubMed ID: 26511987
[TBL] [Abstract][Full Text] [Related]
18. Quality of life during first-line palliative chemotherapy for recurrent and metastatic head and neck cancer with weekly cisplatin and docetaxel.
Guntinas-Lichius O; Rühlow S; Veelken F; Klussmann JP
J Cancer Res Clin Oncol; 2009 Jul; 135(7):901-8. PubMed ID: 19085003
[TBL] [Abstract][Full Text] [Related]
19. Changes in health related quality of life in women and men undergoing radiation treatment for head and neck cancer and the impact of smoking status in the radiation treatment period.
Egestad H; Emaus N
Eur J Oncol Nurs; 2014 Aug; 18(4):339-46. PubMed ID: 24877857
[TBL] [Abstract][Full Text] [Related]
20. Quality of life in patients with locally advanced head and neck squamous cell carcinoma undergoing concurrent chemoradiation with once-a-week versus once-every-3-weeks cisplatin.
Menon NS; Noronha V; Patil VM; Joshi A; Bhattacharjee A; Kalra D; Laskar SG; Mathrudev V; Nawale K; Bhelekar AS; Prabhash K
Cancer Med; 2022 Nov; 11(21):3939-3948. PubMed ID: 35343648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
